Printer Friendly

Safety and efficacy of Aceclofenac in osteoarthritis patients.

INTRODUCTION: Osteoarthritis (OA) is one of the most common, chronic, musculoskeletal disorder particularly affects the knee and hip joints in elderly people (1) .OA rarely occurs before the age of 40 but by the age of 75 at least 85% of the populations have either clinical or radiographic evidence of osteoarthritis (2). Its prevalence after the age of 65 is about 60% in men and 70% in women (3). OA is a disease of synovial joints characterized by cartilage loss with accompanying peri-articular bone response (4). Cartilage is a protein substance that serves as a "Cushion" between the bones of the joints (5). Osteoarthritis is also known as degenerative arthritis (6). The term osteoarthritis implies an inflammatory disease (7). OA is associated with pain and inflammation of the joint capsule, impaired muscular stability, reduced range of motion and functional disability (8).

Risk factors for OA include advanced age (9), female gender (10), genetic predisposition (11), obesity (12), and joint injury including trauma, repetitive use, and prior inflammation. Genes that encode Collagen type II have been proposed as candidate genes for familial OA (13,14). Radiographs can help confirm OA when the diagnosis is uncertain from clinical examination. It is usually not difficult to differentiate OA from a systemic rheumatic disease, such as rheumatoid arthritis, because joint involvement in the latter disease is usually symmetric and polyarticular, with arthritis in wrists and metatarsophalangeal joints (sites not usually involved in OA) and constitutional features such as prolonged morning stiffness, fatigue, weight loss, or fever may be seen (15). Synovial fluid analysis reveals mild leukocytosis is i.e. with a predominance of mononuclear cells. Synovial fluid analysis is of particular value in excluding other conditions, such as calcium pyrophosphate dehydrates deposition disease, gout or septic arthritis (16).

The 2000 American College of Rheumatology (ACR) Subcommittee on osteoarthritis Guidelines recommends that pharmacologic interventions be used only as adjuncts to Non Pharmacologic measures. The evidence supporting Non-Pharmacological therapies is sparse and is mainly limited to the treatment of knee osteoarthritis (17). A Cochrane review from 200118 concluded that land-based therapeutic exercise seemed to reduce pain and improves function in symptomatic osteoarthritis of the knee. Orally administered NSAIDs play an important role in the symptomatic management of osteoarthritis. It is estimated that more than 30 million people worldwide take NSAIDs (19).

While NSAIDs are effective in the management of pain and inflammation in a large number of conditions including osteoarthritis, it is now well established that they are associated with the development of upper gastrointestinal (GI) damage including mucosal erosions, ulcers and life-threatening conditions like perforations and hemorrhage (20). This led to the development of cyclooxygenase-2 (COX-2) inhibitors. The potential advantage of COX-2 inhibitors is that they have fewer adverse effects on the gastrointestinal tract as a result of having less inhibitory effect on the gastro protective prostaglandins produced by COX-1 enzymes in the gastrointestinal tract. This advantage of COX-2 selective NSAIDs has been demonstrated in many trials (21,22).

However, the cardiovascular safety of these drugs was found to be controversial. Three independent randomized trials and a cumulative meta-analysis (23) confirmed excess cardiovascular risk as well as serious skin reactions were also seen with Rofecoxib and valdecoxib (24). A preferential COX-2 inhibitor is expected to be safer than a conventional NSAID in its propensity to cause GI adverse effects, and at the same time, unlike highly selective COX-2 inhibitors, it will not leave COX-1 activity unopposed and thus may have reduced propensity for cardiovascular adverse events (25).

Aceclofenac is an effective analgesic and anti-inflammatory agent provides symptomatic relief in a variety of painful conditions (26). Aceclofenac appears to be particularly well tolerated among the NSAIDs with a lower incidence of gastro intestinal adverse effects. This good tolerability profile results in a reduced withdrawal rate and greater compliance with treatment (27). Aceclofenac inhibits synthesis of the inflammatory cytokines like interleukin (IL)-1, Tumor necrosis factor (TNF), and Prostaglandin E2 (PGE2) production (28). Since long-term NSAID treatment is indicated for osteoarthritis, the ideal agent should have good efficacy and a low propensity to cause adverse events. Hence the present study was carried out in osteoarthritis patients to evaluate the safety and efficacy of Aceclofenac.

MATERIALS AND METHODS: The patients were recruited after obtaining their informed consent. The study protocol was approved by the Institutional Ethics Committee of M.R.Medical College, Gulbarga, Karnataka. The study recruited 65 osteoarthritis patients of which 29 were male and 36 female patients. The age of the patients were ranged between 40-60 years, suffering from the OA for at least 6 months. In this study demographic characteristic such as age, sex and diagnosis were recorded (Table 1). A thorough general physical examination was done. Laboratory investigations such as Complete blood count, LFT, Serum electrolytes, Serum creatinine, RBS, Urine analysis, Stool occult blood and X-ray of the knee joint were carried out before drug administration and after the completion of treatment.

Eligible Patients received Aceclofenac 100 mg twice daily were administered orally for 3 months.

Inclusion criteria: 1. Male and female patients who were [greater than or equal to]40 years of age. 2. Radiological diagnosed with osteoarthritis of the knee. 3. With a minimum Western Ontario Mac Master (WOMAC) Index score of 40, Visual Analogue Scale (VAS) score of 4 mm. 4.Whose disease status worsened by at least one point on the 0-4 LIKERT Scale.

Exclusion criteria: 1. Patients with a history or showing the presence of other Rheumatic disease that would be responsible for secondary osteoarthritis. 2. Patients with a history of peptic ulcers. 3. Patient with a history of bleeding disorders. 4. Patients with renal impairment. 5. Alcoholic liver disease. 6. Pregnant or lactating woman. 7. Uncontrolled medical conditions like Severe Anemia, Hypertension, Congestive cardiac failure and Bronchial asthma. 8. History of hypersensitivity to Aceclofenac or other NSIADs. 9. Patient who had previously received Aceclofenac was also excluded from the study.

Clinical examination was done at screening after 1, month, 2 month and 3 month. The outcome of the therapy was based on the improvement of the clinical manifestations of osteoarthritis and tolerability of the drug.

Clinical Assessments: Clinical assessment was done by calculating WOMAC scores (29), time taken to walk a distance of 100 feet, Visual Analogue Scale Scores (30) for pain, investigator's assessment on a LIKERT scale (31) and joint tenderness. Tolerability assessment was based on adverse events as well as compliance. Adverse events were monitored and noted at every visit.

Statistical Analysis: For parametric data, Student's t-test and Chi-square goodness-of-fit tests were used, whereas for non-parametric data RIDIT analysis was used.

RESULTS:

Adverse effects: Less common adverse events were cough, constipation, headache and rhinorrhea. No clinically significant biochemical changes were observed in any of the patients.

Safety: With regard to safety, Aceclofenac was found to be safe in terms of Epigastric discomfort, dyspepsia and abdominal pain. Patient's compliance was also better with Aceclofenac. Physician rating of treatment showed Aceclofenac was statistically safe and well tolerated.

DISCUSSION: Until recently the new COX-2 selective inhibitors have been increasingly used. They have equal efficacy to standard NSAIDs. However the cardiovascular safety of these drugs was found to be controversial (32,33). Aceclofenac has been evaluated in international studies and is indicated for the relief of pain and inflammation associated with rheumatoid arthritis, osteoarthritis or Ankylosing spondylitis (34). This study evaluates its efficacy and safety in patients with osteoarthritis. Aceclofenac has also shown stimulatory effects on cartilage matrix synthesis that may be linked to the ability of the drug to inhibit IL-1. IL-1 suppresses various growth factors. Inhibition of IL-1 thus stimulates synthesis of cartilage matrix. There is also evidence that Aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human articular chondrocytes subjected to inflammatory stimuli (35) and that 4'-hydroxyaceclofenac has chondro protective properties attributable to suppression of IL-1 mediated promatrix metalloproteinase production and proteoglycan release (36,37). Thus Aceclofenac may prevent the degradation of articular connective tissue in patients with rheumatoid arthritis and osteoarthritis, and should be classified as a unique NSAID.

Based on the findings of the study provides evidence that Aceclofenac is effective in the treatment of osteoarthritis. However, Aceclofenac was found to be statistically significant in certain aspects of efficacy such as WOMAC scores, investigator's assessment and joint tenderness. Aceclofenac was found to be statistically significant in terms of epigastric discomfort, dyspepsia, abdominal pain and compliance.

There is no significant change in the parameters of laboratory investigations including complete blood count, serum creatinine, blood urea, Serum electrolytes, RBS, LFT, RFT, urine analysis, stool occult blood before and after the treatment.

Whether Aceclofenac may have less propensity to cause cardiovascular adverse events due to its preferential COX-2 inhibition (38,39), will need further evaluation. Aceclofenac may be an alternative to non-selective NSIADs as well as to selective COX-2 inhibitors for the treatment of patients with osteoarthritis or rheumatoid arthritis.

CONCLUSION: Aceclofenac has anti-inflammatory, analgesic properties and gastrointestinal damage is less. This may be due to preferential inhibition of COX-2. This study shows that Aceclofenac is a safe, effective and well tolerated drug for osteoarthritis.

BIBLIOGRAPHY:

(1.) Walker-Bone K, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BJM 2000; 321: 936-40.

(2.) Jamsen E, Jantti P, Puolakka T, et al. Primary knee replacement for primary osteoarthritis in the aged: gender differences in epidemiology and preoperative clinical state. Aging Clin Exp Res. 2012 Dec; 24(6):691-8.

(3.) Sarzi-Puttini P, Cimmino MA, Scarp R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005; 35: 1-10.

(4.) Shipley M, Black CM, Denton CP, Compston J, O'Gradaigh D. Rheumatology and bone disease. In: Kumar P, Clark M, editors. Clinical Medicine. Philadelphia: Elsevier Saunders; 6th ed (2005) pp. 529-603.

(5.) William C., Shiel J. et al. Medicinenet.com/Osteoarthritis/article.html.2007.

(6.) Liu-Bryan R Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep. 2013 May; 15(5):323. doi: 10.1007/s11926-013-0323-5.

(7.) Fadda SM, Gamal SM, Elsaid NY, Mohy AM. Resistin in inflammatory and degenerative Rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression. Z Rheumatol. 2013 Aug; 72(6):594-600.

(8.) Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomized placebo controlled trials. BMJ 2004; 329: 1317.

(9.) Hagen ND, Olson T, Millett P. Comprehensive post-arthroscopic management of a middle-aged adult with glenohumeral osteoarthritis: a case report. Int J Sports Phys Ther. 2013 Feb; 8(1):54-61.

(10.) Macrini TE, Coan HB, Levine SM, Lerma T, Saks CD et al. Reproductive status and sex show strong effects on knee OA in a baboon model. Osteoarthritis Cartilage. 2013 Jun; 21(6):839-48.

(11.) Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013 Mar; 146(3):185-96.

(12.) Koonce RC, Bravman JT. Obesity and osteoarthritis: more than just wear and tear. J Am Acad Orthop Surg. 2013 Mar; 21(3):161-9.

(13.) Seki K, Fujimori T, Savagner P et al. Mouse Snail family transcription repressors regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan. J Biol Chem. 2003 Oct 24; 278(43):41862-70.

(14.) Li G, Han N, Li Z, Q. Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis. Clin Rheumatol. 2013 May; 32(5):609-15.

(15.) Duncan AE, Colman RJ, Kramer PA. Longitudinal study of radiographic spinal osteoarthritis in a macaque model. J Orthop Res. 2011 Aug; 29(8):1152-60.

(16.) Lia Wang J, Fu Y, o W, Li Z, Wang H, Bai X. Proteomic analysis of synovial fluid: insight into the pathogenesis of knee osteoarthritis. Int Orthop. 2013 Jun; 37(6):1045-53.

(17.) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.

(18.) Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of the hip or knee. In: The Cochrane Library, Issue 3. PP 346-350. Chichester, UK: John Wiley and Sons; 2004.

(19.) McCarberg B, Tenzer P. Complexities in the pharmacologic management of osteoarthritis pain. Curr Med Res Opin. 2013 May; 29(5):539-48.

(20.) Essex MN, Bhadra P, Sands GH. Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res. 2012; 40(4):1357-70.

(21.) Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitors, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-27.

(22.) Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43: 370-7.

(23.) Juni P, Nartey L, Reichenbach S, et al. Rosk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9.

(24.) Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.

(25.) Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors--a new generation of safer NSAIDs? Aliment Pharmacol Ther. 1997 Apr; 11(2):227-36.

(26.) Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001; 61: 1351-78.

(27.) Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacotherapy 2004; 5: 1347-57.

(28.) Maneiro E, Lopez-Armada MJ, Fernandez-Sueiro JL, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol. 2001 Dec; 28(12):2692-9.

(29.) Torres-Claramunt R, Leal J, Hinarejos P et al. Correlation Study between KSS, WOMAC and SF-36 Scores in Patients Undergoing Total Knee Arthroplasty in a Spanish Speaking Population. J Arthroplasty. 2013 Mar 21. S 0883-5403.

(30.) Hutchison AM, Pallister I, Evans RM, et al. Intense pulsed light treatment of chronic mid-body Achilles tendinopathy: A double blind randomized placebo-controlled trial. Bone Joint J. 2013 Apr 1; 95-B (4):504-9.

(31.) Parmigiani L, Furtado RN, Lopes RV, et al. Joint lavage associated with triamcinolone hexacetonide injection in knee osteoarthritis: a randomized double-blind controlled study. Clin Rheumatol. 2010 Nov; 29(11):1311-5.

(32.) Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nationwide cohort study after the withdrawal of Rofecoxib. Europe Heart J. 2012 Aug; 33(15):1928-30

(33.) Carman WJ, Su S, Cook SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):754-62.

(34.) Pareek A, Chandurkar N, Gupta A, et al. Efficacy and safety of Aceclofenac-cr and Aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentre, double-blind study. 2011 May; 12(5):546-53.

(35.) Maneiro E, Lopez-Armada MJ, Fernandez-Sueiro JL, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol 2001; 28: 2692-9.

(36.) Akimoto H, Yamazaki R, Hashimoto S, et al. 4-Hydroxy-aceclofenac suppresses the interleukin-1 induced production of promatrix metalloproteinase and release of sulphated-glycosaminoglycans from rabbit articular chondocytes. Europ J Pharmacol 2000; 401: 429-36.

(37.) Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4-hydroxyaceclofenac, suppresses the production of interstitial pro-collagenase/ProMMP-1 and prostro-melysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000; 49: 133-8.

(38.) Pavelka K. A comparison of the therapeutic efficacy of Diclofenac in osteoarthritis: a systematic review of randomized controlled trials. Curr Med Res Opin. 2012 Jan; 28(1):163-78.

(39.) Paul S, Das N, Ghosh S. The effects of Aceclofenac and Nabumetone in osteoarthritis. JNMA J Nepal Med Assoc. 2009 Apr-Jun; 48(174):121-5.

Anand R Kanaki [1], Ravi D Mala [2], Jeevangi Santosh Kumar [3], Prasanna Jewargi [4], Srinivas Raikar [5]

PARTICULARS OF CONTRIBUTORS:

[1.] Assistant Professor, Department of Pharmacology, M R Medical College, Gulbarga.

[2.] Assistant Professor, Department of Pharmacology, M R Medical College, Gulbarga.

[3.] Associate Professor, Department of Pharmacology, M R Medical College, Gulbarga.

[4.] Assistant Professor, Department of Pharmacology, M R Medical College, Gulbarga.

[5.] Post Graduate Student, Department of Pharmacology, M R Medical College, Gulbarga.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Anand R Kanaki, Assistant Professor, Department of Pharmacology, M.R. Medical College, Sedam Road, Gulbarga--585105. Email--anandkanaki@yahoo.com

Date of Submission: 18/09/2013.

Date of Peer Review: 19/09/2013.

Date of Acceptance: 09/10/2013.

Date of Publishing: 15/10/2013

Table 1: Demographic data (mean [+ or -] SD)

Parameters                 Aceclofenac Group
                               (n = 65)

No. of patients          65
Male: Female             29:36
Age (years)              53.63 [+ or -] 5.23
Weight (Kg)              62.18 [+ or -] 9.26
Pulse (Rate/min)         77.06 [+ or -] 6.49
Systolic BP (mmHg)       117.81 [+ or -] 10.99
Diastolic BP (mmHg)      78.21 [+ or -] 7.12
Respiratory (Rate/min)   16.66 [+ or -] 0.90
Patient with edema       0

Table 2: Screening visit parameters (mean [+ or -] SD)

Parameters                                    Aceclofenac

WOMAC score                            52.1568 [+ or -] 11.52588
Time taken to walk 100 feet (sec)      79.9570 [+ or -] 44.9455
Symptom scores for pain on 0-10 VAS    5.4729 [+ or -] 3.652
Weight bearing                         4.379 [+ or -] 1.763585
Pain at rest Active                    5.2365 [+ or -] 2.02

Table 3: WOMAC scores at baseline and after
1, 2 and 3rd month treatment (mean [+ or -] SD)

             Aceclofenac group

Baseline    50.65 [+ or -] 12.12
1st Month   40.45 [+ or -] 10.38
2nd Month   34.29 [+ or -] 9.74
3rd Month   27.41 [+ or -] 9.91

Table 4: Time (in seconds) taken to walk
100 feet in distance baseline and after
1st month, 2nd month and 3rd month.

                Aceclofenac

Baseline    96.69 [+ or -] 18.28
1st Month   91.68 [+ or -] 16.70
2nd Month   84.75 [+ or -] 20.03
3rd Month   79.42 [+ or -] 15.93

Table 5: Visual analogue scale (VAS) scores for
pain at baseline and after 1st month, 2nd month
and 3rd month treatment (mean [+ or -] SD)

Pain on weight bearing               Aceclofenac group

                             Left Knee            Right Knee

Baseline                 5.29 [+ or -] 1.83   5.11 [+ or -] 1.90
1st month                4.30 [+ or -] 1.76   4.15 [+ or -] 1.89
2nd month                3.53 [+ or -] 1.55   3.32 [+ or -] 1.64
3rd month                2.57 [+ or -] 1.40   2.43 [+ or -] 1.41

Table 6: Outcome of therapy (efficacy
and safety) as assessed by the Physician
after 3rd month of treatment.

                        Aceclofenac n [%]

Efficacy *     High          41 (63%)
             Moderate        18 (27%)
               Mild           2 (3%)
Safety *       Good          44 (67%)
             Moderate        17 (26%)
               Poor           0 (0%)
COPYRIGHT 2013 Akshantala Enterprises Private Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ORIGINAL ARTICLE
Author:Kanaki, Anand R.; Mala, Ravi D.; Kumar, Jeevangi Santosh; Jewargi, Prasanna; Raikar, Srinivas
Publication:Journal of Evolution of Medical and Dental Sciences
Article Type:Report
Date:Oct 21, 2013
Words:3098
Previous Article:Awareness about anesthesia and anesthesiologist among the paramedical staffs of SN medical college, Bagalkot (Karnataka).
Next Article:A rare case of auto-immune hepatitis.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters